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Abstract: Macular edema is a common cause of visual loss in patients with retinal vein 
  occlusions. Ozurdex®, a dexamethasone intravitreal implant, has been shown in randomized 
controlled trials to reduce macular edema and improve visual acuity in patients with either 
branch retinal vein occlusions or central retinal vein occlusions. It was approved in the United 
States in 2009. Since then, new therapeutic agents and clinical data have emerged. The purpose 
of this review is to critically evaluate the clinical utility of Ozurdex® in the current treatment 
strategy of macular edema related to retinal vein occlusion.
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Introduction
Retinal vein occlusion (RVO) is the second most common retinal vascular disorder after 
diabetic retinopathy.1 Macular edema is an important cause of visual loss in patients 
with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). 
In 2009, Ozurdex®, a dexamethasone (DEX) intravitreal implant (Allergan, Inc., Irvine, 
CA) became the first therapy approved by the US Food and Drug Administration (FDA) 
for this indication. A year later, ranibizumab (Lucentis®, Genentech Inc., South San 
Francisco, CA), a monoclonal antibody fragment that binds to and inhibits vascular 
endothelial growth factor (VEGF), became the second therapy to be approved. Currently, 
the off-label use of intravitreal triamcinolone acetonide (TA), and bevacizumab 
(Avastin®, Genentech Inc., South San Francisco, CA), another VEGF inhibitor, are also 
popular treatments for macular edema secondary to RVO.
During the past 2 decades, the management of macular edema associated with RVO 
has been influenced largely by 2 pivotal trials conducted by the National Institutes of 
Health (NIH): the Branch Vein Occlusion Study (BVOS) and the Central Vein Occlu-
sion Study (CVOS). In BVOS, patients with BRVO, macular edema with best-corrected 
visual acuity (BCVA) of 20/40 or worse, and no macular nonperfusion on fluorescein 
angiography (n = 139) were randomized to focal argon laser photocoagulation or no 
treatment.2 After 3 years of follow-up, the laser group (n = 48) gained an average of 
1.33 lines compared with 0.23 lines in the nontreatment group (n = 35; P = 0.001). It 
was observed that macular edema spontaneously resolved in up to   one-third of patients. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Therefore, the investigators from the BVOS recommended 
waiting 3 months before considering laser treatment. In the 
CVOS, patients with CRVO and macular edema with BCVA of 
20/50 or worse (n = 155) were randomized to grid laser photo-
coagulation (n = 77) or no treatment (n = 78).3 Although there 
was a reduction in macular edema on fluorescein angiography 
(31% of laser group versus 0% of no treatment group) at the 
1-year follow-up, there was no difference in BCVA between 
the 2 groups at any time point over a 3-year period. The CVOS 
investigators did not recommend laser treatment for CRVO. 
Until recently, there was no proven, effective therapy for vision 
loss associated with macular edema secondary to CRVO.
Corticosteroids exhibit anti-inflammatory properties, 
reduce vascular permeability, inhibit fibrin deposition, 
stabilize endothelial cell tight junctions, and inhibit the 
synthesis of VEGF, prostaglandins, and other cytokines.4 
Small case series were published in 2002 supporting the use 
of triamcinolone, in the form of Kenalog®−40 (40 mg/L TA 
suspension, Bristol-Myers Squibb, Princeton, NJ), but the data 
were limited by small sample size, weak methodology, and 
lack of appropriate controls. The NIH sought to evaluate TA 
in the form of Trivaris® (Allergan Inc, Irvine, CA) for BRVO 
and CRVO in a randomized controlled fashion. The Standard 
Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) 
Study compared 1-mg and 4-mg intravitreal triamcinolone with 
standard of care (grid photocoagulation in eyes without dense 
hemorrhage and deferral of photocoagulation until hemorrhage 
clears in eyes with dense macular hemorrhage for BRVO and 
observation for CRVO).5,6 At the 12-month visit, there was no 
statistically significant difference in VA among the 3 groups 
with BRVO. However, the adverse rate event, particularly 
elevated intraocular pressure and cataract, were highest in 
the 4-mg group. The SCORE investigators advised that grid 
photocoagulation remain the benchmark against which other 
treatments are compared in clinical trials evaluating BRVO.
In contrast, intravitreal triamcinolone was determined 
to be superior to observation for macular edema in patients 
with CRVO. There was no statistically significant differ-
ence in efficacy between the 1-mg and 4-mg groups but the 
adverse rates of elevated intraocular pressure and cataract 
were higher in the 4-mg group. The SCORE investigators 
recommended 1-mg intravitreal triamcinolone for up to 
1 year and possibly 2 years.
Design and pharmacology 
of Ozurdex®
DEX is a water-soluble, synthetic glucocorticoid that 
is three times more potent than TA7 on a molar basis. 
  Intravitreal injection directly delivers the drug to the 
  vitreous but DEX is rapidly cleared from the vireous with 
an estimated half-life of 5.5 hours in humans.8 The DEX 
intravitreal implant contains poly(D,L-lactide-co-glycolide) 
which degrades into lactic acid and glycolic acid. The 
drug–copolymer complex is inserted into the eye through 
the pars plana using a 22 gauge injector and releases a total 
dose of 0.7 mg of DEX.
Chang-Lin et al recently published their results on the 
pharmacokinetics and pharmacodynamics of Ozurdex®.9 
They inserted 0.7 mg DEX implants into both eyes of 
34 male monkeys (Macaca fascicularis) and collected 
blood, vitreous humor, and retina samples at days 7, 30, 60, 
90, 120, 150, 180, 210, 240, and 270 after administration. 
Three monkeys without implants served as the control group. 
DEX was quantified by liquid chromatography–tandem mass 
spectrometry while gene expression of the DEX-sensitive 
gene cytochrome P450 A38 (CYP3A8) was evaluated by 
real-time reverse transcription-polymerase chain reaction as a 
marker of biological   activity. It was observed that the opaque, 
round cylindrical implant became translucent, fragmented, 
and smaller after day 60. DEX was detected in the retina 
and vitreous humor for 6 months, with peak concentrations 
during the first 2 months. After 6 months, DEX was below 
the limit of quantitation. DEX concentrations in the retina 
were characterized by 2 distinct phases, which corresponded 
to the fragmentation of the implant. From days 7 to 60, 
high concentrations of DEX were detected, with the mean 
peak DEX concentration (Cmax = 1110 ± 284 ng/g) recorded 
on day 60. From days 90 to 210, low concentrations of 
DEX were detected with the mean concentration at the 
last detectable time of Clast = 0.0167 ± 0.0193 ng/g at day 
210. DEX concentrations in the vitreous humor were also 
characterized by two distinct phases (days 7 to 60 and days 
90 to 180). Cmax = 213 ± 49 ng/mL measured at day 60. 
Clast = 0.00131 ± 0.00194 ng/mL at day 180. In comparison, 
a standard 0.4-mg intravitreal injection of TA in humans 
provides an initial concentration of 100,000 ng/mL assuming 
a 4-mL vitreous humor volume. DEX was   present at low 
concentrations in plasma at all time points. Biodegradable 
implants typically follow a triphasic drug release pattern 
consisting of an initial drug burst, sustained release, and a 
final drug burst.10,11 But Ozurdex® does not exhibit a final 
drug burst. Compared with control eyes, CYP3A8 expression 
in the retina was upregulated 3-fold up to 6 months after 
injection of the implant. The steady state concentrations of 
DEX observed in monkey eyes are expected to be similar 
to those in humans.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Efficacy studies, including 
comparative studies
Two randomized, prospective, masked, sham-controlled 
studies were conducted at 167 clinical sites in 24 countries 
to evaluate the safety and efficacy of Ozurdex® over an 
initial 6-month period followed by a 6-month open-label 
extension (unpublished data).12 The results were pooled for 
analysis because the study designs were identical. Patients 
had to be at least 18 years of age with decreased vision due 
to clinically detectable macular edema related to CRVO 
or BRVO. Duration of ME had to be between 6 weeks and 
9 months for CRVO and between 6 weeks and 12 months 
for BRVO. Only 1 eye per patient could be selected. If both 
eyes were eligible, then the eye with the shorter duration of 
ME was selected. BCVA was between 34 letters (20/200) 
and 68 letters (20/50) in the study eye and better than 34 
letters in the fellow eye. Retinal thickness in the central 
subfield on OCT had to be greater than 250 microns in the 
study eye. Key exclusion criteria included the presence of 
clinically significant epiretinal membrane, active retinal or 
optic disc neovascularization, active or history of choroidal 
neovascularization, presence of rubeosis iridis, any active 
infection, aphakia or anterior chamber intraocular lens, 
clinically significant media opacity, glaucoma, or current 
ocular hypertension requiring more than 1 medication to 
control intraocular pressure in the study eye, or a history 
of steroid-induced intraocular pressure rise in either eye. 
Patients were also excluded if they had diabetic retinopa-
thy in either eye, had any uncontrolled systemic disease, 
were currently using or anticipating the use of systemic 
steroids or anticoagulants during the study, or had any 
ocular condition in the study eye which, in the opinion of 
the investigator, would prevent a 15-letter improvement in 
visual acuity. Patients were randomized to either a sham 
procedure (n = 426) or treatment with 0.35 mg (n = 414) 
or 0.7 mg (n = 427) DEX implant using a 1:1:1 allocation 
ratio. The sham procedure followed the same anesthetic 
and preparation protocol as the treatment arm but used a 
needleless applicator placed against the conjunctiva to simu-
late placement of study medication. Patients did not receive 
grid photocoagulation in the control arm. Randomization 
was performed using an interactive voice response sys-
tem and stratified by BRVO or CRVO. All patients were 
examined at baseline, and at 1, 7, 30, 60, 90, and 180 days 
after treatment. Masked graders at a central reading center 
(University of Wisconsin Fundus   Photograph Reading 
center) evaluated OCT measurements using a standard 
protocol. The intent-to-treat population was used for data 
analysis. Initially, the primary outcome for the first study 
was the proportion of eyes achieving at least a 15-letter 
improvement from baseline at day 180. The FDA later 
changed the primary outcome for the second study to be the 
time to reach a 15-letter improvement from baseline. When 
interpreting the results, it is important to note that Ozurdex® 
is meant to release intraocular levels of dexamethasone for 
6 months. Following completion of the first portion of the 
study, patients were eligible to have open label retreatment 
with Ozurdex 0.7 mg regardless of which initial treatment 
group they were in, sham, 0.35 mg, or 0.7 mg, provided that 
they demonstrated evidence of comparable macular edema 
on OCT examination at 6 months.
The cumulative response rate was 41% in the 0.7 mg 
group, 40% in the 0.35 mg group, and 23% in the sham 
group (P , 0.001). Although the proportion of eyes achieving 
at least a 15-letter improvement from baseline BCVA was 
greater in the treatment groups at month 1 (21% in the 0.7 mg 
group vs 18% in the 0.35 mg group vs 8% in the sham 
group; P , 0.001) and month 3 (22% in the 0.7 mg group 
vs 23% in the 0.35 mg group vs 13% in the sham group; 
P , 0.001), this effect was no longer statistically significant 
at month 6. The reduction in mean OCT central subfield 
retinal thickness was greater in the 0.7 mg (208 ± 201 µm) 
and 0.35 mg (177 ± 197 µm) groups than in the sham group 
(85 ± 173 µm) at month 3 (P , 0.001), but not statistically 
significant at month 6.
Currently, there is no randomized controlled trial compar-
ing anti-VEGF agents and Ozurdex® directly. At 12 months, 
Campochiaro et al determined that with monthly treatment of 
ranibizumab in the first 6-month period and then as needed 
treatment in the second 6 month period, mean change in 
VA from baseline for patients with BRVO was +7.3, +16.6, 
and +18.3 letters for control, 0.3 mg ranibizumab, and 
0.5 mg ranibizumab, respectively.13 At 12 months, Brown 
et al found that with monthly treatment of ranibizumab in 
the first 6 month period and then as needed treatment in the 
second 6 month period, mean change in VA from baseline 
for patients with CRVO was +0.8, +12.7, and +14.9 letters 
for control, 0.3 mg ranibizumab, and 0.5 mg ranibizumab, 
respectively.14 A disadvantage to anti-VEGF treatment is the 
need for frequent injections.
In patients with BRVO treated with Ozurdex®, mean 
change in VA from baseline was approximately +6.6 letters 
for retreated patients and +6.5 letters for delayed treatment. In 
patients with CRVO treated with Ozurdex®, mean change in 
VA from baseline was approximately +2.2 letters for retreated 
patients and −1.2 letters for delayed treatment.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Safety and tolerability 
of the Ozurdex® implant
The safety and tolerability of a sustained-release implant are 
particularly important due to the long duration of exposure to 
the drug and the drug vehicle, in some cases up to 6 months. 
In addition, the relative difficulty of explantation makes the 
recognition of any and all associated serious adverse events 
paramount. The safety of the implant may be divided into 
several categories: complications arising from the implan-
tation procedure; toxicity or immunoreactivity associated 
with exposure to the implant polymer; and toxicity associ-
ated with exposure to the agent itself, both in the immediate 
and long term. In addition, the rate of drug release from the 
implant is crucial to maintaining the concentration of drug 
inside the eye and at the vitreoretinal interface within the 
safe therapeutic window.
Patient intolerance of an implantable drug delivery device 
may be associated with symptomatic local or systemic toxic-
ity of either the drug or the implant vehicle; the implanta-
tion procedure, including local irritation or reaction at the 
implantation site; or even anxiety and other psychological 
stress with regard to the invasive nature of the procedure.
Polymer toxicity
The DEX intravitreal implant is composed of a biodegradable 
co-polymer of lactic acid and glycolic acid impregnated with 
a variable dose of DEX. The use of this co-polymer for slow 
release drug delivery was initially described over 30 years 
ago for a variety of applications, including antimalarial drugs, 
contraception, and anesthetics. Multiple in vitro and in vivo 
studies have confirmed its biocompatibility.15,16 Intramuscular 
implantation results in a mild foreign body reaction similar 
to the degree seen in response to synthetic suture material, 
while in vivo studies of intravitreal implantation show virtu-
ally no ocular toxicity.16,17
Dexamethasone toxicity
Early animal studies determined that a high concentration 
of DEX could be achieved intravitreally without any clini-
cal, histological, or electrophysiological toxicity. Kwak and 
D’Amico found increasing levels of retinal toxicity occur-
ring at doses above 800 µg administered to rabbits; however, 
another study found that up to 4.8 mg of DEX was tolerated 
intravitreally with no adverse consequences.18,19 Another 
animal study of a poly (lactide-co-glycolide) DEX implant 
found that the intraocular DEX concentration was constant 
over time, and that electroretinographic studies confirmed 
no change in normal retinal physiology.18
Clinical trials
An early trial of the DEX implant compared 0.35 mg and 
0.7 mg doses to a noninjection observation group for the 
treatment of macular edema of various etiologies. In the 
study, a number of ocular adverse events occurred in each 
of the treatment groups, including anterior chamber cell and 
flare, vitreous hemorrhage, and ocular pain or irritation. The 
majority of these events occurred within the first 7 days after 
injection, and the only events that occurred at a significantly 
higher rate after this period were anterior chamber flare (5%) 
and elevated intraocular pressure (6%), both occurring in 
the 0.7 mg group only. Intraocular pressure increases of 
greater than 10 mmHg or to an absolute level of 25 mmHg 
occurred in less than 20% of each DEX group, and all 
instances of ocular hypertension were managed medically. 
The rate of cataract formation was not significantly higher 
in either treatment group than in the observation group 
throughout the 180-day study period.20
Several adverse events were believed to be related to 
traumatic implantation; thus, a subsequent study compared 
the safety profile of surgical implantation with that of a novel 
proprietary applicator device.21 Use of the applicator device 
was associated with a lower overall incidence of ocular 
adverse events (68.4% vs 90%), although this difference was 
not statistically significant. Of note, there were no reports of 
vitreous hemorrhage in the applicator group, compared with 2 
out of 10 patients in the incisional group who experienced this 
complication. However, the study was insufficiently powered 
to determine a statistically significant difference for this or 
any other infrequently occurring adverse event.
The largest published clinical trial of the DEX implant 
to date has compared visual, anatomic, and safety outcomes 
over 6 months in patients with macular edema from central 
or branch retinal vein occlusion. The overall incidence of 
ocular adverse events was comparable to previous studies, 
at a rate of 62.9% in the 0.7 mg group and 61.9% in the 
0.35 mg group. This was significantly higher than the rate of 
42.8% in the sham procedure group.21 Only 3 specific events 
(eye pain, ocular hypertension, and anterior chamber cellular 
reaction) occurred at a significantly higher rate than in the 
sham group. Although the incidence of ocular hypertension 
was higher in the treatment groups, the vast majority of cases 
were transient instances of elevated intraocular pressure, 
which were managed either by observation or with topical 
medications alone. Intraocular pressure typically reached a 
peak at 2 months, decreasing steadily over the next 4 months. 
At this peak time point, the authors reported that 16% of all 
patients had a pressure of greater than 25 mmHg. Of note, the Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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proportion of patients using ocular antihypertensive agents 
increased from 6% at study entry to 24% at 6 months among 
all patients in the treatment group. An increase of at least 
10 mmHg from baseline was seen in 12.6% of study eyes 
at 2 months after the first DEX implant and 15.4% of study 
eyes at 2 months after the second DEX implant.12 Over the 
total 12-month study period, 32.8% of retreated DEX 0.7/0.7 
patients had at least a 10 mmHg increase from baseline at 
some point over the 12-month period. Ultimately, fourteen 
eyes required laser or surgery to reduce intraocular pressure. 
The rate of cataract formation was not significantly different 
in any treatment group than in the sham group during the 
first 6 months. However, over the 12-month study period, 
cataracts were reported in 29.8% of phakic study eyes in the 
retreated DEX 0.7/0.7 group, 19.8% of the DEX 0.35/0.7 
group, and 10.5% of the delayed treatment (sham/0.7) group 
(P = 0.001). Eleven patients underwent cataract surgery 
(unpublished data).
Quality of life measures
Among the most important factors in determining patient 
perception of a treatment modality is a risk–benefit analy-
sis, in which the potential effectiveness of a treatment is 
weighed against the probability, severity, and treatability 
of adverse events. Additionally, patient perceptions of the 
disease process and its likely prognosis with and without 
treatment are likely to influence a patient’s choice to pro-
ceed with treatment. Finally, the invasiveness and perceived 
discomfort of the treatment can be a significant factor in the 
decision-making process.
Although central and branch vein occlusions occur fre-
quently, only a few studies have objectively examined their 
impact on patient quality of life. Awdeh et al and Deramo 
et al examined the vision-related quality of life indices in 
patients with branch and central retinal vein occlusions, 
respectively, using the National Eye Institute Visual Func-
tion Questionnaire (VFQ-25). Each found significantly 
lower scores than a normal reference group in almost all 
subscales, including areas such as general health, driv-
ing and reading vision, dependency, social functioning, 
and mental health.22,23 Additionally, Chang et al surveyed 
patients with macular edema resulting from vein occlusion 
in order to determine a vision preference value (a value 
validated in patients with age-related macular degeneration), 
and found similar values to those patients with subfoveal 
choroidal neovascularization. They also found that greater 
than two-thirds of these patients showed some enthusiasm 
for intravitreal injection in order to improve vision, despite 
the somewhat invasive nature of the procedure, suggesting a 
significant impact of the diseases on visual functioning.24 We 
may speculate that patients with vein occlusion might also 
express enthusiasm in other relatively invasive   treatments 
such as the DEX intravitreal implant.
Place in therapy and conclusion
In the recent phase III trial that randomized the DEX implant 
against a sham treatment, the DEX implant demonstrated 
short term clinical efficacy by several metrics, including the 
percentage of patients achieving a 10- to 15-letter improve-
ment in vision; the rate at which patients achieved visual 
improvement; the mean improvement in vision; and central 
macular subfield thickness as measured by OCT. At 6 months, 
however, the proportion of patients achieving a 15-letter 
improvement (a primary outcome measure in the study) was 
no longer significantly higher than sham. Subgroup analyses 
of CRVO and BRVO showed a similar pattern, with the peak 
effect as measured by mean change in vision and propor-
tion of patients improved occurring at study month 2 with a 
reduction in effect through month 6.
By comparison, we may refer to recent data comparing 
intravitreal TA to the standard of care for the treatment of 
macular edema secondary to branch and central retinal vein 
occlusion (SCORE study).5,6 For the treatment of BRVO, 
respectively 25.6% and 27.2% of patients receiving 1-mg and 
4-mg doses of TA at 4-month intervals improved 15 letters in 
the first year, compared with 28.9% in the grid laser group. 
These values are comparable to the month 2 results in BRVO 
arm of the DEX implant study, in which 30% and 26% of 
eyes in the 0.7 mg and 0.35 mg groups, respectively, showed 
a 15-letter improvement. However, patients in this study were 
eligible to be retreated with laser or triamcinolone prior to the 
6-month time point, which was not permitted in the Ozurdex 
study, to some extent limiting direct comparison. Similarly, 
TA for the treatment of CRVO resulted in 25.6% and 26.5% of 
patients in the 1-mg and 4-mg groups improving 15 letters in 
the first year, compared with 6.8% of patients in the standard 
of care (observation) group. This was also comparable to the 
DEX implant study group, in which 29% and 33% of patients 
in the 0.7 mg and 0.35 mg groups, who experienced the same 
increase in vision at the peak response time of 2 months post 
implantation. In each of the TA groups, patients received an 
average of 2 injections in the first year.
Adverse events occurring in the SCORE study included 
increase in intraocular pressure necessitating initiation of 
pressure-lowering medication; progressive lens opacity; and 
minor adverse events including conjunctival hemorrhage and Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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vitreous floaters. Although the rates of elevated IOP (up to 
41%) and progressive lens opacity (up to 35%) were signifi-
cantly higher in the SCORE study than in patients receiving 
the DEX implant, these results, as well as those showing clini-
cal efficacy, should be compared with caution, in the absence 
of direct randomized, comparative controlled trials.
Ranibizumab has also been used with success in the 
treatment of macular edema associated with both BRVO and 
CRVO. The recently published BRAVO and CRUISE stud-
ies showed a significant proportion of patients achieving a 
15-letter improvement with an average of almost one injection 
per month. For BRVO, 55.2% and 61.1% of patients receiving 
0.3 mg and 0.5 mg of ranibizumab achieved this outcome 
by 6 months.25 For CRVO, 15 or more letters were gained by 
46.2% and 47.7%, respectively.26 Central macular thickness 
as measured by OCT showed a corresponding decrease, while 
the occurrence of adverse events was not significantly differ-
ent from the sham injection group of either study. Again, in 
the absence of a randomized, clinical trial comparing these 
treatments, direct comparisons between these studies and the 
DEX implant studies should only be made with caution.
The DEX implant has two potential advantages over other 
therapies currently employed for macular edema secondary 
to vein occlusion. The continuous release of medication 
maintains a consistent level of the drug within the eye over 
an extended period, eliminating the need for monthly or 
bimonthly injections, as might be necessary with intravitreal 
anti-VEGF agents. Additionally, the sustained release for-
mulation provides the potency of DEX while compensating 
for the short intraocular half-life of the medication.
Still undetermined, however, are long-term adverse events 
associated with the implantation, including the incidence of 
cataract and glaucoma. Increased intraocular pressure was 
certainly noted in more than one study, although at 6 months, 
did not approach the level seen with the use of TA in the 
SCORE study. Cataract formation at 6 months was negli-
gible; however, the authors of the DEX implant phase III 
trial have recognized that the initial study period may be 
insufficient to demonstrate significant progression of lens   
opacity. Indeed, as-yet unpublished 12-month data suggest 
that the DEX implant does increase the risk of cataract.
In summary, the DEX intravitreal implant is a minimally 
invasive treatment modality that has shown initial clinical effi-
cacy in the treatment of macular edema resulting from retinal 
vein occlusion. Randomized clinical trials have shown that, in 
the short term, it improves vision, as well as decreases the risk 
of vision loss after a single intervention. However, most patients 
may ultimately still attain only a modest or temporary, though 
measurable, improvement in vision with a single injection, and 
repeat injection is usually necessary for most CRVO patients. 
That does not appear to be the case for BRVO patients where 
the natural history, as well as treatment outcomes, appears 
more favorable. Thus, the DEX implant is an additional phar-
macologic agent in our arsenal. It may be most appropriate for 
motivated, phakic, or pseudophakic patients with simple branch 
retinal vein occlusions associated with macular edema and 
significant hemorrhage, who are unwilling or unable to tolerate 
more frequent intravitreal injections required for anti-VEGF 
therapy, or for patients who have demonstrated intolerance or 
recalcitrant edema following anti-VEGF therapy. It may also 
be a suitable choice for patients with CRVO, particularly those 
who are already pseudophakic and not steroid responders, and 
who are not good candidates for anti-VEGF agents for other 
reasons such as intolerance or pre-existing thromboembolic 
disease. For patients with only a minimal response to the DEX 
implant, monotherapy with additional implants would not be 
recommended. Some consideration might be given to combi-
nation therapy with both an anti-VEGF agent and DEX or TA. 
If, after discussion, the patient and physician prefer a steroid 
agent to anti-VEGF therapy, intravitreal TA is a reasonable, but 
shorter acting alternative, and has also been shown to exhibit 
prolonged bioavailability in the eye. Beer et al performed the 
first human study to determine intravitreal TA concentration by 
measuring aqueous samples after a single 4 mg intravitreal TA 
injection. They found the half-life in nonvitrectomized eyes to 
be 18.6 days and estimated that TA can be present in the eye 
for up to 3 months after injection.27 Mason et al studied both 
the aqueous and vitreous concentrations after intravitreal TA 
injection in 6 eyes and also found detectable levels in patients 
sampled approximately 3 months from the time of injection.28 
Although the sample size was small in both studies, they are 
consistent with other small clinical results and our own clini-
cal observations. The smaller gauge needle and significantly 
smaller cost of TA may be preferable to some physicians and 
patients but not others. Further study, including randomized 
trials comparing the DEX implant to grid laser in BRVO, intra-
vitreal anti-VEGF agents, and triamcinolone, are anticipated 
to help clarify some of these issues.
Disclosure
None of the authors have a direct proprietary interest in any 
of the products used in this study. Dr Blumenkranz has served 
as a consultant to Allergan, the manufacturer of Ozurdex, and 
the Triamcinolone formulation for the SCORE Study. He 
has also been a consultant to Genentech, the manufacturer 
of ranibizumab and bevacizumab.Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1049
Dexamethasone intravitreal implant for macular edema
References
  1.  Rogers S, McIntosh RL, Journ GD, et al. The prevalence of retinal vein 
occlusion: pooled data from population studies from the United States, 
Europe, Asia, and Australia. Ophthalmology. 2010;117:313–319.
  2.  The Branch Vein Occlusion Study Group. Argon laser   photocoagulation 
for macular edema in branch vein occlusion. Am J Ophthalmol. 
1984;98:271–282.
  3.  The Central Vein Occlusion Study Group. Evaluation of grid pat-
tern photocoagulation for macular edema in central vein occlusion: 
the Central Vein Occlusion Study Group M report. Ophthalmology 
1995;102:1425–1433.
  4.  Leopold IH. Nonsteroidal and steroidal anti-inflammatory agents. 
In: Sears Ml, Tarkkanen A, editors. Surgical Pharmacology of the Eye. 
New York: Raven Press, 1985:83–133.
  5.  Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial compar-
ing the efficacy and safety of intravitreal triamcinolone with observa-
tion to treat vision loss associated with macular edema secondary to 
central retinal vein occlusion: the Standard Care vs Corticosteroid for 
Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 
2009;127:1101–1114.
  6.  Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial compar-
ing the efficacy and safety of intravitreal triamcinolone with standard 
care to treat vision loss associated with macular Edema secondary to 
branch retinal vein occlusion: the Standard Care vs Corticosteroid for 
Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 
2009;127:1115–1128.
  7.  Edelman  JL.  Differentiating  intraocular  glucocorticoids. 
Ophthalmologica. 2010;224(Suppl 1):25–30.
  8.  Gan IM, Ugahary LC, van Dissel JT, van Meurs JC. Effect of intravitreal 
dexamethasone on vitreous vancomycin concentrations in patients with 
suspected postoperative bacterial endophthalmitis. Graefes Arch Clin 
Exp Ophthalmol. 2005;243:1186–1189.
  9.  Chang-Lin JE, Attar M, Acheampong AA. Pharmacokinetics and 
pharmacodynamics of a sustained-release dexamethasone intravitreal 
implant. Invest Ophthalmol Vis Sci. 2011;52:80–86.
  10.  Kuno N, Fujii S. Biodegradable intraocular therapies for retinal 
  disorders: progress to date. Drugs Aging. 2010;27:117–134.
  11.  Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. 
Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res. 
2004;23:253–281.
  12.  Haller JA, Bandello F, Belfort R, et al. Randomized, Sham-Controlled   
Trial of Dexamethasone Intravitreal Implant in Patients with   Macular   
Edema Due to Retinal Vein Occlusion. Ophthalmol. 2010;117: 
1134–1146.
  13.  Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for   macular 
edema following branch retinal vein occlusion. Ophthalmology. 
2010;117:1102–1112.
  14.  Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macu-
lar edema following central retinal vein occlusion. Ophthalmology. 
2010;117:1124–1133.
  15.  Visscher GE, Robison RL, Maulding HV , et al. Biodegradation of and 
tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. 
J Biomed Mater Res. 1985;19:349–365.
  16.  Moritera T, Ogura Y, Honda Y, et al. Microspheres of biodegradable 
polymers as a drug-delivery system in the vitreous. Invest Ophthalmol 
Vis Sci. 1991;32:1785–1790.
  17.  Fialho SL, Rego MB, Siqueira RC, et al. Safety and pharmacokinetics 
of an intravitreal biodegradable implant of dexamethasone acetate in 
rabbit eyes. Curr Eye Res. 2006;31:525–534.
  18.  Nabih M, Peyman GA, Tawakol ME, Naguib K. Toxicity of high-dose 
intravitreal dexamethasone. Int Ophthalmol. 1991;15:233–235.
  19.  Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and phar-
macokinetics of dexamethasone after intravitreal injection. Arch Oph-
thalmol. 1992;110:259–266.
  20.  Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized 
controlled study of an intravitreous dexamethasone drug delivery 
system in patients with persistent macular edema. Arch Ophthalmol. 
2007;125:309–317.
  21.  Haller JA, Dugel P, Weinberg DV , et al. Evaluation of the safety and 
performance of an applicator for a novel intravitreal dexamethasone 
drug delivery system for the treatment of macular edema. Retina. 
2009;29:46–51.
  22.  Deramo VA, Cox TA, Syed AB, et al. Vision-related quality of life in 
people with central retinal vein occlusion using the 25-item National 
Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 
2003;121:1297–1302.
  23.  Awdeh RM, Elsing SH, Deramo VA, et al. Vision-related quality of life 
in persons with unilateral branch retinal vein occlusion using the 25-item 
National Eye Institute Visual Function Questionnaire. Br J Ophthalmol. 
2010;94:319–323.
  24.  Chang MA, Fine HF, Bass E, et al. Patients’ preferences in choosing 
therapy for retinal vein occlusions. Retina. 2007;27:789–797.
  25.  Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular 
edema following branch retinal vein occlusion: six-month primary 
end point results of a phase III study. Ophthalmology. 2010;117: 
1102e1–1112e1.
  26.  Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for   macular 
edema following central retinal vein occlusion: six-month primary 
end point results of a phase III study. Ophthalmology. 2010;117: 
1124e1–1133e1.
  27.  Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and 
pharmacokinetics of triamcinolone acetonide after a single intravitreal 
injection. Ophthalmology. 2003;110:681–686.
  28.  Mason JO, Somaiya MD, Singh RJ. Intravitreal concentration and 
clearance of triamcinolone acetonide in nonvitrectomized human eyes. 
Retina. 2004;24:900–904.